Drugs / Epelsiban
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02703181 | Jul → Sep 2015 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02257359 | Dec 2014 → Jan 2015 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02213029 | Aug 2014 → Feb 2016 | — | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01669083 | Aug 2012 → Mar 2013 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00549211 | Oct 2007 → ? | pregnancy disorder, premature ejaculation | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02794467 | Jul → Oct 2016 | adenomyosis | GlaxoSmithKline | Withdrawn | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01021553 Comparator | Dec 2009 → May 2011 | premature ejaculation | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epelsiban | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02257359 ↗ |
| Known as | EPELSIBAN BESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2037511 ↗ |
| Known as | GSK-557296B | ChEMBL registry synonym — accepted as the source's own label CHEMBL2037511 ↗ |
| Known as | GSK557296 | “Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female...” NCT02213029 ↗ |
| Action | Inhibit | “selective oxytocin receptor antagonist” PMID 23937679 ↗ Aug 20131“Oxytocin receptor antagonist” CHEMBL2037511 ↗ |
| Modality | Small molecule | — CHEMBL2037511 ↗ |
| Route | Oral | “Single and Repeat Oral Doses” NCT00549211 ↗ |
| Target | OXTR | “Oxytocin receptor antagonist” CHEMBL2037511 ↗ |